| Product Name |
Clopidogrel Inhouse Impurity 23 / Clopidogrel camphorsulfonate
|
| Product Category |
Impurities, Intermediates |
| Sub-Category |
Metabolites, Pharmaceutical Standards, Fine Chemicals |
| CAS No |
120202-68-8 |
| Catalog Number |
GS.91.CLD.133 |
| Chemical Name/Synonyms |
Methyl (S)-2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate ((1R,4S)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonate; [(1R,4S)-7,7-Dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl]methanesulfonic acid;methyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)acetate; |
| Molecular Weight |
554.12 |
| Molecular Formula |
C16H16ClNO2S.C10H16O4S |
| Purity |
NLT 95 % |
| Appearance |
White to Off-White Crystalline Powder |
| Solubility |
DMF, Acetone, Methanol & Water |
| Applications |
Clopidogrel Camphorsulfonate is used to prevent heart attack and stroke in people who are at high risk of these events, including those with a history of myocardial infarction and other forms of acute coronary syndrome, stroke, and those with peripheral a |
| Inventory Status |
QC Pending
|
